Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers.
Background Impact of BRAF V600E mutations (BRAF V600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumo...
| Published in: | Oncologist Vol. 30; no. 3; pp. 1 - 10 |
|---|---|
| Main Authors: | , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Oxford University Press / USA
Mar2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184296452&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 184296452 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10837159 IJ7 jtl: Oncologist issn: 10837159 maglogo: N pubinfo: dt: Mar2025 vid: 30 iid: 3 pid: 622 pub: Oxford University Press / USA artinfo: ui: 184296452 184296452 184296452 10.1093/oncolo/oyaf044 184296452 ppf: 1 ppct: 9 formats: tig: atl: Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers. aug: au: Mahipal, Amit Bucheit, Leslie Zhang, Nicole Barnett, Reagan M Storandt, Michael H Chakrabarti, Sakti affil: University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States sug: subj: Gastrointestinal Neoplasms Drug Therapy Transferases Gastrointestinal Neoplasms Diagnosis Liquid Biopsy Mutation Decision Making, Clinical Human Genomics Chi Square Test Overall Survival Gastrointestinal Neoplasms Prognosis Outcome Assessment Descriptive Statistics DNA Gastrointestinal Neoplasms Epidemiology ab: Background Impact of BRAF V600E mutations (BRAF V600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAF V600E, understanding the frequency and impact of BRAF alterations across non-CRC GI cancers is essential for clinical decision-making. Methods Patients with PDAC, GEA, HCC, or CCA who had cell-free DNA detected on Guardant360 (Guardant Health) from 2020 to 2023 were queried. Prevalence of characterized BRAF genomic alterations (GA) was calculated; GAs were grouped by class (Class I/II/III). The Chi-squared test assessed differences between cancer types. A subset of patients had outcomes analysis using GuardantINFORM, a real-world clinicogenomic database, to derive real-world overall survival (rwOS). Results Of 32 480 included patients, BRAF GAs were identified in 4.4%; 19% were BRAF V600E (0.81% prevalence overall). CCA had the highest rate of BRAF GAs and BRAF V600E (P < .01); HCC and GEA had the highest rates of BRAF class II/III alterations. There were no significant differences in rwOS by alteration class or cancer type; numeric differences were observed by alteration class. Few patients were treated with BRAF inhibitors (2.2%). Prevalence of co-occurring alterations was unique by cancer type. Conclusions Frequency of BRAF GAs, including BRAF V600E, in non-CRC GI cancers detected by liquid biopsy is similar to tissue-based rates and can be reliably used to assess BRAF status. BRAF GAs have mixed prognostic implications on survival for patients with non-CRC GI malignancies that warrant further exploration. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|